Atlas FDA

ECONOLITH LITHOTRIPTER

FDA premarket approval P950043/S006 · decided 1999-08-27

Approval details

PMA number
P950043
Supplement
S006
Supplement type
Normal 180 Day Track
Supplement reason
Postapproval Study Protocol
Trade name
ECONOLITH LITHOTRIPTER
Generic name
Lithotriptor, extracorporeal shock-wave, urological
Applicant
Medispec, Ltd.
Date received
1999-05-19
Decision date
1999-08-27
Days to decision
100 days
Decision code
APRL
Product code
LNS
Advisory committee
Gastroenterology, Urology
Expedited review
No
Location
Montgomery Village, MD
Statement
Approval for the final report of the postapproval study regarding the possible relationship between extracorporeal shcok wave lithotripsy and the onset of hypertension, and 2) modifications tothe Econolith(TM) Lithotripter's labeling to reflect the results of the final report. Based upon the information submitted, FDA believes that the postapproval report demonstrates that hypertension is not a long-term risk of extracorporeal shock wave lithotripsy, and that the postapproval requirement is now

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Omnispec ED1000 (K210166)Medispec, Ltd.2023-01-27
ECONOLITH EM1000 (K063504)Medispec, Ltd.2007-03-09
ECONOLITH E3000, MODEL 3000 (SW-6) (K040461)Medispec, Ltd.2004-05-25
LITHOSPEC(TM) INTRACORPOREAL LITHOTRIPTER (K974796)Medispec, Ltd.1998-03-12